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COMPLEMENT ACTIVATION IN BULLOUS SKIN DISEASES 
ROBERT E. JORDON, M.D. 
C utaneous Immunopathology Unit and the Departments of Dermatology and Immunology, Mayo Clinic and Mayo 
Foundation, Rochester, Minnesota 
Pemphigus, bullous pemphigoid, cicatricial pemphigoid, dermatitis herpetiform is, and 
herpes gestation is are members of the chronic vesiculobullous skin diseases of man. The 
complement system, including both the classical and alternative pathways, may be 
important in the pathogenesis of these diseases. In pemphigus, early complement compo-
nents (Cl, C4, and C2) appear to be activated in addition to later components (C3 and C5), 
suggestive of classical pathway activation. Participation of properdin in addition to early 
complement components suggests local activation of both complement pathways in bullous 
pemphigoid and cicatricial pemphigoid. Herpes gestation is and dermatitis herpetiformis 
may be bullous skin diseases entirely mediated by the alternate or properdin pathway . 
The specific immunopathologic findings in these diseases are discussed . 
The complement system represents a group of 
serum proteins which, when reacting sequentially, 
participate in the humoral phase of the inflamma-
. tory response (1 ,2 ]. Recent ev idence from several 
investigators suggests that this system of proteins 
is involved in the pathogenesis of some of the 
bullous skin diseases of man. In this review, I shall 
consider brief1y how the complement system is 
activated, and subsequently describe our present 
knowledge of complement activation in the bullous 
skin diseases of man and the manner in which the 
complement system may be rel ated to the patho-
genesis of these diseases. 
THE COMPLEMENT PATHWAYS 
The classic mechanism of complem ent activa-
t ion (now referred to as the " class ical pathway") 
involves an interaction between the first compo-
nent (C1), through a subunit (C1q), and human 
immunoglobulins (IgG1, IgG2, IgG3, and IgM) 
that have been aggregated or altered by combina-
tion with antigen (1,2 ]. This interaction leads to 
the activation of C4 and C2, which forms an 
enzyme C42 or C3 convertase [1] . C3 convertase 
then activates C3 and the remainder of the comple-
ment cascade and generates biologically active 
substances which mediate inf1ammation . 
An "alternate pathway " of complement activa-
tion has been described by Gotze and MUller-
Eberhard (3 ]. In this pathway , now recognized to 
be the old properdin system desc ribed by Pillemer 
et al (4] in the early 1950s, the early complement 
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components (C1, C4, and C2) are not activated. 
Instead, the terminal components (C3 through C9) 
are activated by a separate system of serum factors 
including properdin, C3 proactivator (C3PA) or 
properdin factor B, and C3PA convertase (3,5,6 ]. 
Properdin is now thought to activate the alternate 
pathway by interacting with C3PA convertase (5) . 
C3PA convertase (also called C3PAase) then con-
verts C3PA to its active form , "C3 activator," 
which then activates C3 [5,6 ]. The activat ing sub-
stances of this pathway include a factor found in 
cobra venom, inulin, zymosan, bacterial endo-
toxins, and aggregates of certain immunoglobulins 
(in particular, IgA) that cannot activate the system 
through the classical pathway [2,3 ]. 
When the third component of complement is 
. activated by either the classical or the alternate 
pathway, two fragments are formed, C3a and C3b. 
C3b can activate C3PAase through a recently 
described (6,7 ] positive feedback mechanism and 
thus can amplify the whole sequence of comple-
ment reaction. The pathways to complement acti-
vation, including the C3b feedback mechanism, 
are illustrated in Figure 1. 
PEMPHIGUS 
Through indirect immunofluorescent (IF) stain-
in g [8- 12), many previous studies have established 
the presence of antiepithelial autoantibodies in the 
serum of patients with active pemphigus. These 
studies have been previously summari zed in an 
extensive review in this journal [11] and in two 
books [8,9]. These autoantibodies are specific for 
an intercellular substance (lCS) of skin and mu-
cosa, and they react prec ise ly at the site of t he 
primary histopathologic lesion in which epidermal 
cells undergo a loss of cohesion (acantholysis) that 
results in intraepidermal bull a form ation . 
Direct IF studies have shown that IgG deposition 
IS locali zed in the ICS areas in virtually all skin 
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FlO. 1. The complement pathways. Fe = crystalizable, 
terminal portion of the antibody molecu le; Fab = Fab 
(antibody combining region) region of the antibody 
molecule; CoVF ~ cobra ven?,m factor ; C~b JNH = C3b 
inhibi tor. (Mod ified from Gotze and Muller-Eberhard 
[5 ], Lachmann and Nicoll7], and Ruddy, Gigli , and 
Austen [2].) 
lesions tested to date [1 2, 13 ). S imilar C3 depos i-
tion on t he other hand , has been demonstrated 
mai~ IY in skin lesions from patients before t he 
applicat ion of corticosteroid therapy [1 4- 16 ). Clq 
and C4 deposition [16,17) , as well as C3, has also 
been demonstrated in ICS areas of early pem -
phigus les ions, suggesting activation via t he class i-
ca l pathway. 
Besides the depos ition of immunoglobulin , Clq, 
and C3, we have recently shown similar ICS 
deposition of C3PA [18 ]. The in tensity of C3PA 
staining, however, was considerably less than that 
of Clq and C3 staining (Fig. 2). In contrast, 
properd in was seen in only two lesions and then 
on ly a round a few acan tholytic ce ll s; properdin 
deposit ion did not occur in early developing acan-
t holytic areas. Because properdin is found infre-
quently but C3PA frequently , such C3PA deposi-
tion may be due to the C3b feedback mechanism 
according to the classical pathway activation out -
lined e·arlier. Table I summ arizes the IF studies of 
early oral and skin lesions from 6 pemphigus 
vu lgaris patien ts studied by us to date (18 ). 
We have a lso recently reported that total hemo-
lytic complement was lower in the blister fluids of 
pemphigus vulga ri s patients than in se rum (Tab. 
II) and other serum and blister fl uids [19 ]. Except 
for some patients with bullous pemphigoid [20), 
most patients wi th other bu llous diseases and 
experimentally induced blisters had total blister 
fluid complement levels which closely approached 
the serum levels. Hemolytic Cl, C4, C2, C3, and 
C5, determined in serum and blister fluid from 2 
pat ients with pemphigus, were not detectable in 
one blister fluid and were extremely low in t he 
second . When measured immunochemica ll y, 
C3PA was absen t from both of t hese bliste r fluids. 
With one exception, all pemphigus blister f1uid s 
have exhibi ted an t icomplementa ry activity when 
tested with normal hu man serum (Tab . II). The 
addition of pemphigus blister fluid to normal 
human serum has a lso resul ted in t he inhibition of 
hemolytic Cl, C2, C3, and C5 (Tab. III). T he 
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FIG. 2. Immunoflu orescent (IF) staining of early lesions 
of pemphigus vulgaris. A: Direct IF staining, demonstrat-
ing intercellular substa nce (lCS) deposition of C3 in ea rly 
acantholytic areas of a skin lesion (x 110) . B: Modified 
indirect IF staining, demonstrating res deposition of 
C3PA in an oral mucosal lesion; although less intense 
than C3, C3PA is apparent on ly in acantholytic areas (x 
110). (From Jordon et al [18], with permission of The 
Williams & Wilkins Co.) 
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T ABLE I. Summary of im m unofl uorescent studies of six 
pemph igus vulgaris les ions" 
In tercell ular stai ning 
JgG 6 
IgA" 4 
IgM 2 
ClqC 4 
C3 6 
C3PN 5 
Properd in" 2 
a These st udies were summ ari zed in a previous report 
11 8 J. 
" Found in oral lesions only. 
C Modified indirect immunol1uorescence used . 
TABL E II . Hem oly tic com plem ent-seru m and blister 
fl uid of patien ts with pemphigus vulgaris" 
Cases 
I 2 3 4 5 
Seru m (S) 14.9 13.4 13.0 11 .6 17.2 
Blister flu id (BF) 3.4 5.0 1.0" 1.9 < 1.0" 
BF/S rat io (%)< 23 37 < 8 16 < 6 
Ant icomplemen- 35 0 100 20 63 
tary act ivity" 
expressed as per-
cent inhi bition 
" Ex pressed in CH50 uni ts/10 mg of total prote in. 
" Too low to measure . 
,. T he rat io of complement in blister fluid t.o compl e-
ment in seru m. 
,/ T he abili ty of the patient's bl iste r l1uid to inhi bi t 
comp lement activity in an equ al volume of norm al 
hum an serum. 
a n t icomple m en ta ry facto r in pemphigus bli ster 
fluid t herefore a ppears to be capa ble of activatin g 
t he class ica l pathway . S imil a r inhibi t ion studies 
wit h con t rol sera a nd blist e r fluid s fa il ed to de mon -
strate such in activation of hem olytic C l , C2, C3, 
and C5 in norm a l hum a n se rum. 
Afte r immunoele'Ctrophoresis with m onospec ifi c 
an t iserum against purified C3 , no C3 act ivi ty was 
noted in blis ter !1 u id from case 3 in T a ble II (Fig. 
3A). The convers ion of C 3 in norm a l hum a n se rum 
by t he " an t icomplem entary facto r" in pemphi gus 
bliste r fluid is a pparen t in Figure 3B. S imila r 
convers ion of C3PA in norm a l hum a n se rum by 
t hi s factor has a lso rece n t ly been d e monstrated 
[19 ]. L ike t he d eposit ion of C3PA in earl y pe m -
p higus les ions de monst rated by IF techniques (18 ), 
t hi s convers ion of C3P A by pemphi gus bliste r fluid 
is pro ba bly bes t expl a ined by C3b feedback ac tiva-
t ion of C3P A th rough C3P A convertase [6,7]. 
The n a ture of' t he an t icomplem en ta ry factor is 
not yet known . It is not destroyed at 56°C for 30 
min , a nd it will act ivate comple m en t both at 37°C 
for 1 hr and 4°C for 8 hI'. Furt her studi es us in g 
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sucrose d ens ity -gradi en t ul t racen t rifugation tec h -
niques (unpublished d ata) indicate t hat t his factor 
is a hi gh-m olecul ar -we igh t prote in a nd m ay re pre -
sen t an immune complex. Furt he r studies of t hi s 
in terestin g pheno menon a re currently in p rogress. 
BULLOUS PEM PHIGOID 
The comple m ent syste m may a lso play a n im -
porta nt role in t he pa thogenes is of bullous pem -
phigoid , a bullous di sease characte ri zed by ubepi -
d erm a l bulla form ation a nd a utoan t ibodi es to t he 
base m ent m e mbra ne zone (BMZ) whi ch can be 
T ABU ; Ill. Inh ibition of hem oly tic co m plem ent 
componen ts in normal hu man serum by pemphiNus 
blister fluid from case 3 (T ab . In" 
Component" 
Assay'! 
CI C2 C3 Cs 
NHS alone 380,000 2,000 1,120 2,700 
NHS + GG VBH b 162,000 925 510 1,300 
PBr alone < 1,000 < 100 < 100 < 100 
NHS P BF 78,000 340 < LOO 530 
lnhi bition (% )'/ 51 63 > 80 59 
" These st udi es were prev iously reported by Jordon et 
al [19 J. 
b NHS = normal human serum ; GGVB++ = glucose-
gela t in- Veronal buffer; PBF = pemphi gus bliste r l1uid. 
" Normal component values reported prev iollsly by 
Day et. al [45 /. 
,/ The amoun t of inhi bit ion produced by P BF for each 
component. in NHS. 
FIG. 3. Immunoelectrophoresis wi th 2% agar. barbital 
buffer (pH 8.5, ionic strength 0.05, and conta ining 0.01 
M EDT A), and potentia l gradient of 6 v/cm for 2 1/2 hr at 
lOoC. A : Blister f1uid (upper well ) and serum (lower well) 
from a pat.ient. with pemphigus vulga ris. C3 was present 
in the serum bu t not in the blister fluid . 8: Mixture of 
norm al hum an serum and pemphigus blist.er fluid (up per 
we ll ), incubated at 37°C for 30 min hows some C3 
conversion. Norm al hum an serum along (lower well) 
shows no C3 conversion. (From J ordon et al [19], with 
perm ission of Clinical and Exp erimental Immunology) 
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FIG. 4. In v itro com plem ent sta ining (C3) of norma l 
hum a n skin wi t h serun~ from a pa tien t wi t h bull ous 
pe mphigo id. Sta lntng of base men t mem brane zone IS 
evident ( x 150). 
dem onstrated by indirec t IF sta inin g 19, 11,21,22 ]. 
As in pemphigus, these autoa nt ibodies react pre-
cisely with their corresponding histopatholog ic 
s ite, t he BMZ area; this may ex pla in t he subepi -
derm a l location of the bull a. 
Us ing direct IF sta ining methods, immunopath -
ologic investiga tions of bu llous pemph igo id lesions 
have cons istently demonstrated BMZ depos it ion of 
IgG and C3 in v irt ua lly a ll skin spec imens exam -
ined to d ate [13,23 ], in cluding 'ome from patien ts 
wit h active di sease but wi thout circulating an t i-
bodies . The d irect IF sta ining pattern is identi ca l 
wit h the indirect IF pat tern. 
Us ing in vit ro complement ta ining methods, we 
have a lso shown that most serologically pos it ive 
bullous pemphigo id sera fix complement (C3) to 
t he BMZ in a patte rn ident ica l wi th that ac hieved 
wit h indirect IF ta ining [24 ]. We h ave recently 
found t hat BMZ autoa ntibodies fi x C1q and C4 in 
addi t ion to C3 (unpublished observa tions), a find-
ing that suggests that " pemrihigo id" a nt ibodi es 
activate the class ica l co mplement pathway. Sa ms 
and Schur [25 J a lso have s hown t ha t mos t co mple-
men t-fi x ing BMZ ant ibodies belong to the IgG3 
subclass which cha racte ris ti ca ll y acti vates th e 
class ica l pathway [2, 3 J. Figure 4 illust rates a 
pos iti ve in vi tro complement sta ining react ion (C3) 
in t he serum of a patien t with bullous pemphigo id . 
By both direct and " modified " indirect IF tec h-
niques, Provos t and T omas i [26J firs t demon -
str ated the depos it ion of fac tors assoc iated with 
t he acti va tion of an a lte rn ate pathway in t he skin 
les ion s of bullous pemphigo id patients. They also 
reported the depos it ion of both properdin and 
C3PA in 6 cases and of C1q, C4, and C3. They have 
recently extended the ir se ries to 16 patien ts [27 ], 
wit h resu lts which a re consistent wi th the act iva-
tion of the class ica l pathway as well as of th e 
alternate pathway. 
We recently confirm ed (28 J t hese in terest in g 
observations in 15 pa ti ents wi t h bu ll ous pem -
phigoid. Our 15 reported cases plus 11 additi ona l 
cases a re summa rized in T able IV. 3. in addi t ion 
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to immunoglobulins, and properdin (F ig. 5) were 
present a long the sk in BMZ in a ll 26 of t he les ions 
studied. However, C3PA deposit ion wa present in 
on Iy 9 of the 26 spec im ens and showed cons idera-
bly less sta ining in tensity than C3 and properd in ; 
t hese findin g differ somewhat from t hose of P rov-
ost and T omas i [26.27 J who reported C3PA 
depos ition in most of their cases. CI q deposition 
was present in a large percentage of both seri es. 
Our IF fin d ings in bullous pemphigo id les ions, 
t herefore, a lso suggest loca l ac ti vat ion of comple-
ment by both the classical and t he a ltern ate 
pathway. 
T tl BLE IV. Summary of immunofluorescent studies of 26 
bu llous pemph i~oid lesions in 26 patien ts" 
IgG 
IgA 
IgM 
Clq" 
C3 
C3PA" 
P ro pe rd in " 
Fibrin 
Basemen! memhrcule 7.one 
st.ai nin g-
23 
4 
7 
22 
26 
9 
26 
14 
" Fift een of t hese we re in a previous re port [28 1. 
,. By mod ifi ed in d ireci immunoflu orescence . 
FIG. 5. Immunoflu orescent sta ining of a bullolls pe m -
phigo id skin les ion demonstrating properdin depos it ion 
along wi th the basement mem brane zone ( 220). 
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F in a lly, com pa red wi t h other se rum and bliste r 
fluid p rote ins tota l hemolytic complem en t a ppears 
to be lower in the blister fI uids of most se rolog icall y 
posit ive bullous pemphigo id patien ts [20 ]. In most 
serolog ica ll y nega tive cases, on t he other hand , 
b li ste r ("]uid complement leve ls clo ely a pproac h 
se rum leve ls (Ta b. V) . Because complemen t activ -
ity in pathologic fluid s is a fun ction oftota l prote in 
content [29 ], a ll of t he serum and blister fluid 
complemen t va lues are expressed in CH 50 uni ts 
per 10 mg of tota l prote in . No a nti complementary 
activi ty has been found in bullous pemphigo id 
blister fluid s to date (20]. 
Except for t he two te rmina l components, C8 a nd 
C9, individua l complement componen ts a ppea r to 
be dec reased in blister fluid s wit h low tota l com-
plemen t levels. Aga in , t he se rum leve ls of t he 
individual com ponents of t he complemen t se -
quence a re relat ively norma l [20,30]. 
Decreased levels of C3PA were not apparen t on 
radi a l immunodiffusion s tudies of bullous pem -
phigo id bliste r f1uids. H owever, wi th immunoelec-
t rophores is and antise rum to C3PA , C3PA conver-
sion was a pparen t in bullous pemphigo id bliste r 
fluid bu t not in serum . S imila r obse rvations have 
a lso been reported by Provost a nd Tom as i [26] . 
All of t he studies to date suggest both class ical 
a nd alternate pathway activat ion of complemen t 
in bullous pemphigo id , but we believe that the 
T ABLE: V. Hemoly tic com plement-serum and blister 
fluid from pat ients with bullous pemphigoid" 
Case IIF Serum Bliste r fluid BF/S li ler' (5) ' (BF)' ratio ( '!'o )d 
1 320 10. 1 < 1.0c < 10 
2 640 22.2 2.5 11 
3 80 23 .9 7.8 32 
4 2.560 11.2 4.5 36 
5 1,280 18.3 6.8 37 
6 80 51.7 20.0 39 
7 1,280 9.0 3.5 39 
8 10, 140 13.6 6.0 44 
9 1.280 15.5 7 .. 5 48 
10 2.560 10.8 5.3 49 
11 640 26.1 13. 1 50 
12 Neg. 17.5 8.9 51 
13 320 21.1 13.7 65 
14 Neg. 7.5 5.5 73 
15 Neg. 9.8 7.8 79 
16 Neg. 7.5 6.0 80 
17 Neg. 11.7 10.6 91 
18 Neg. 12.4 11 .8 95 
19 640 8.2 8.3 102 
" Ten of these cases were summ ari zed in a prev ious 
report l20 J. 
"Tiler of baseme nt membrane antibodies as deter· 
mined by ind irect immunoflu orescence. 
(" Expressed in CH50 uni ts/10 mg of tota l prote in . 
,/ The rat io of complement in blister fluid to comple· 
ment in se ru m. 
,. Too low to measure. 
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T ABL E: VI. Summary of immunofluorescent studies of shin 
lesions of cicatricial pemphigoid" 
IgG 
IgA 
IgM 
C3 
C4 
Base ment membrane zone 
sta in ing 
19/24 
7/23 
5/23 
16/23 
1/1 
" From Bean et al l32 ], Dantzig [36 ], Griffith el al [33 ], 
Holubar, Honigsmann, and Wolff [34J, and Tagami and 
Ima mura [35 ]. 
cl ass ical pathway is prima rily involved. IgG depo-
s it ion is presen t in vir t ua ll y all bullous pemphigoid 
les ions [8,9, 13,23 ]. The IgG subclasses t hat fix to 
t he BM2 in vitro a ppear to be t hose capa ble of 
classical pathway activation [25 ]. Complement-
fixin g BM2 antibodies in t he serum of bullou s 
pemphigoid pat ients will fix C lq and C4 in addi -
t ion to C3 (unpublished obse rvations). Profiles of 
t he hemolytic complem en t componen ts in t h e 
blister fluid s of most serologically posit ive bullou s 
pemphigoid patien ts reveal depressed levels of 
early component (Cl , C4, and C2) as well as of 
la ter components [20]. 
CICATRI CIAL PEMPHIGOID 
Cicatrici a l pemphigo id (benign mucous mem-
brane pemphigoid) is a well-defined clinica l entity 
characterized by eros ive, sca rring, blisterin g le-
sions of the mucous m embranes, parti cul a rly of t h e 
ora l mucosa and t he ocul a r membranes [31]. As in 
t rue bullous pemphigo id , the histopathologic hall -
m ark is subepidermal bulla form ation. 
Recent IF investigations reveal BM2 locali za-
t ion ofIgG in ora l, derm al, and conjunctiva l les ions 
of cicatri cia l pemphigo id [32-35 ]. The pattern of 
staining is linear and identica l with the IF pattern 
seen in t rue bullous pemphigoid . Although the two 
diseases appear to be clinica lly different, t he 
s imil ar IF findings sugges t a poss ible etioloaic 
relat ionship between t hem . Further support for 
such a relationship is the demonstration of circu-
la ting BM2 a ntibodi es in the serum of 3 recent ly 
reported cases [35,36] . 
T a ble VI summ a ri zes direct IF studies per-
formed on lesions of cica tri cial pe mphigo id a nd 
reported in the world literature. BM2 deposition of 
C3, as well as immunoglobulin deposit ion , ha 
been demonstrated [33,34 ] and suggest s that COffi-
ple~ent activation plays an importa nt pathoge-
netI c role in cicatricia l pemphigo id. In one re-
ported case, the demonstration of C4 deposition 
suggested classical pathway involvement [34]. 
We recen t ly had t he opportunity to study 10 
cases of cica tri cia l pemphigo id wi t h IF 
tec hniques . * None of the patients had the serum 
* Rogers RS Ill, Bean SF, Perry HO, Jordon RE: 
Unpublished observations. 
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FIG. 6. ~ire.ct immunofluorescent sta.inin~ of a cicatri-
cial pemphigoid ora l lesion demonstratmg lmear depos i-
tion of C3 (x 150). 
antibod ies seen in patients with true bullous pem -
phigoid ; however, a ll patients had linear BMZ 
deposition of IgG and C3 (Fig . 6) in their lesions. In 
addition, depos ition of Clq , C4, C3PA, and proper-
d in suggested activation of · both classical and 
a lternate pathways loca lly in cicatri cial pem-
phigoid lesions. These findings, identica l with 
recent observations in true bullous pem phigoid 
[26-28 ], a lso suggest an etiologic relationsh ip be-
tween these two diseases. 
DERMATITIS HERPETIFORM IS 
Dermatit is herpetiform is, like cicatricia l and 
bullous pemphigoid, is cha racterized by subepider-
mal bulla formation and may a lso represent an 
im munologically mediated disease. Specifically, 
IgA deposition, first described by Van der Meer 
[37 ], has now been well established [38-40 ] at the 
dermal-epiderm al junction in uninvolved skin and 
in skin adjacent to vesicular lesions. The positive 
IgA staining usually appears gran ular or fibrillar 
and is us ually located in t he upper derm is and the 
dermal papillae. In a few instances, however, IgA 
staining appears as a con t inuous band along the 
BMZ, identical to the IgG pattern observed in 
bullous pemphigoid . 
Holubar, Doralt, and Eggerth [39 ] first ca lled 
attention to complement deposition (C3) in derma-
titis herpetiform is, particularly in sk in adjacent to 
vesicular lesions. Because IgA can not activate t he 
classical complemen t pathway, activation by the 
alternate pathway was obvious. C3 deposition in a 
dermatitis herpetiform is lesion is depicted in Fig-
ure 7. 
Seah et a l [41 ] recently reported the absence of 
Clq deposition in 31 of 34 early dermatitis herpeti-
formis lesions despite t he deposition of IgA and C3. 
In t!Ie. three biopsy specimens in which Clq was 
detectab le, IgG or IgM was also present. Their 
find ings were consistent with alterna te pathway 
activation. These same investigators [42J have also 
demonstrated circu lating lOS immune complexes 
in the serum of patients with dermatitis herpetifor-
mis. 
In a more recent study, Provost and Tomasi [43] 
COMPLEMENT ACTIVATION IN BULLOUS SKIN DISE ASES 167 
found C3PA deposition in 4 of 7 patients studied· 
properdin deposi t ion was present in only 1 of thes~ 
7 patients. Clq deposition occurred in 1 case, and 
C4 was not detected. All 7 patients demonstrated 
typ ica l IgA deposition in the derm al papi ll ae. 
Although these findings suggest alternate pathway 
activation, further studies are necessary to sub-
stant iate thi s conclusion. 
HERPES GESTATIO IS 
Herpes gestation is, a rare vesicu lobu llous der-
matosis of pregnancy and the postpartum period, 
may a lso represen t an immunopathologic disease 
mediated by the complemen t system. In a recen t 
report, Provost and Tomasi [26 ] described IF 
findi ngs in 2 patients with herpes gestation is. One 
patient demonstrated BMZ deposition of proper-
din , C3, and C5 in the absence of Clq and 
immunoglobu lins. No BMZ antibodies were pres-
ent in the serum of either of these patients. A 
heat- labi le humoral factor (or factors) was detecta-
ble in the serum of both patients. This factor was 
capable of depositing C3, but not Clq or C4, on 
normal skin BMZ . These findings suggest loca l 
a lternate pathway activation of complement in 
patients with herpes gestation is. 
We recently had the opportuni ty to study an 
in teresting patient with herpes gestation is [44 J. 
She had developed a widespread eruption of iri s 
lesions with periphera l subepidermal vesicles and 
bullae and marked blood eosinophilia. Direct IF 
studies of an early skin biopsy specimen revealed 
properdin and C3 deposition without Clq or immu -
noglobulins (Tab. VII). However, a serum sam ple 
at that time revealed BMZ antibodies of t he IgG 
type to a titer of 1:80. A second skin biopsy about 3 
weeks later revealed deposition of IgG , Clq , C3, 
and properdin at the BMZ. These findings, strik-
ingly similar to those reported recently in bullous 
pemphigoid [26-28 ], suggest involvement of both 
pathways in herpes gestation is. The latter may be 
pathogenetically re lated to bullous pemphigoid 
. FIG. 7. Direct im munofluorescent ta ining of a derma-
titiS herpetiformis sk in lesion demonstrating granular 
deposition of C3 (x 180). 
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T ABLE VlI . Summ ary of imm unofl uorescent studies of 
two shin biopsies from a patien t with herpes f?es tatianis" 
An tise rum 
TgG 
JgA 
TgM 
C lqc 
C3 
C3PN 
P roperd in" 
Biopsy 1 Biopsy 2' 
+ 
+ 
+ 
+ + 
" These studies were p rev iously reported by Bushkell , 
J o rdon , a nd Goltz l44 j . 
/, Obta ined a p p rox ima te ly 3 wee ks a fte r biopsy l. 
C M odified indi rec t immunoflu orescence used . 
FIG .. 8. D irect immunofluorescen t s t a ining of a herpes 
gestation is skin les ion dem onstrating linear d eposit ion of 
C3( x 220). 
rath e r t h a n to oth e r sube pide rm a l bullo us d e r -
m atoses s u c h a s d e rmatiti s h e rpetiformi s . 
W e n ow h ave h a d t h e o ppo rt uni t y to study 3 
a ddi t io n a l p atie n ts w it h h e rpes gestation is . Non e 
o f t h ese h as c irc ul at in g BMZ a n t ibodies in th e 
serum . In a ddi t ion , in a ll 3 p a tie n ts, depos it ion o f 
pro pe rdin a nd C3, in t h e a b se n ce o f immunoglo bu -
lins a nd C lq , in s kin les io n s h as been d e m o n strate d 
by direct IF sta inin g (Fi g. 8). These 3 p at ie n ts , 
t h e refore, a r e immuno logica lly s imil a r to t h e 2 
pat ie n ts d escribed by Provost a nd T o m as i [26 J. 
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